Fused pyrimidine compounds

Patent metadata

Field	Value
Publication number	US-9701677-B2
Application number	US-201514998074-A
Country	US
Kind code	B2
Filing date	Dec 23, 2015
Priority date	Dec 24, 2014
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

First claim

What is claimed is:

1. A compound of Formula (I),

or a tautomer thereof,
wherein:
X is N, Y is CR 3 , and Z is CR 3 ; or X is CR 3 , Y is CR 3 , and Z is N; or X is CR 3 , Y is N, and Z is CR 3 ;
R 1 is —H, —CN, —OR a , C 1-6 haloalkyl, or halogen;
R 2 is —H, —NR a R b , —OR a , or C 1-10 alkyl which is optionally substituted with 1, 2, 3, 4 or 5 R 20 groups, which may be the same or different;
each R 3 is independently —H, —OR a , halogen, —NR a R b , —C(O)OR a , —CN, —NHC(O)NR a R b , —OC(O)NR a R b , —CH 2 C(O)NR a R b , C 1-10 alkyl optionally substituted with 1, 2, 3, 4 or 5 R 20 groups which may be the same or different, or C 1-10 heteroalkyl optionally substituted with 1, 2, 3, 4 or 5 R 20 groups, which may be the same or different;
R 4 and R 5 are independently halogen, —OR a , or C 1-10 alkyl optionally substituted with 1, 2, 3, 4 or 5 R 20 groups, which may be the same or different;
each R 6 is independently halogen, —OR a , or C 1-10 alkyl optionally substituted with 1, 2, 3, 4 or 5 R 20 groups, which may be the same or different;
n is an integer from 0 to 4;
each R 20 is independently C 1-10 alkyl, C 1-10 heteroalkyl, aryl, heteroaryl, halogen, —OR a , —C(O)R a , —C(O)—OR a , —C(O)NR a R b , —OC(O)NR a R b , —NR a C(O)OR b , —S(O) 0-2 R a , —S(O) 2 F, —S(O) 2 NR a R b , —NR a S(O) 2 R b , —N 3 , —CN, or —NO 2 ,
wherein each C 1-10 alkyl, C 1-10 heteroalkyl, aryl, or heteroaryl is optionally substituted with 1, 2, 3, 4 or 5 halogen, —OR a , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —OC(O)NR a R b , —NR a C(O)OR b , —S(O) 0-2 R a , —S(O) 2 F, —S(O) 2 NR a R b , —NR a S(O) 2 R b , —N 3 , —CN, or —NO 2 groups, which may be the same or different;
each R a and R b is independently —H, —NH 2 , C 1-10 alkyl, C 1-10 heteroalkyl, aryl, or heteroaryl, each of which is optionally substituted with 1, 2, 3, 4 or 5 R 21 groups, which may be the same or different; or R a and R b together with the atoms to which they are attached form a C 1-10 heterocycloalkyl; and
R 21 is C 1-6 alkyl, —CN, aryl, heteroaryl, or halogen;
or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 2 is —H, —NR a R b , or —OH.

3. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 2 is —NH 2 or —OH.

4. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein each R 3 is independently —H, —OR a , halogen, —NR a R b , or —C(O)OR a .

5. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein each R 3 is independently —H or C(O)OR a .

6. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein each R 3 is —H.

7. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are each independently halogen, —O—C 1-6 alkyl, or C 1-6 alkyl optionally substituted with 1, 2, 3, 4 or 5 R 20 groups, which may be the same or different.

8. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are each independently C 1-3 alkyl.

9. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —H, —CN, —O—C 1-6 alkyl, —C 1-3 haloalkyl, or halogen.

10. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula Ia:

or a tautomer or pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are —CH 3 .

12. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 2 is —NH 2 .

13. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —H, —CN, —O—C 1-3 alkyl, —CF 3 , or halogen.

14. The compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —CN.

15. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula Ib:

or a tautomer or pharmaceutically acceptable salt thereof.

16. The compound of claim 15 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are —CH 3 .

17. The compound of claim 15 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 2 is —NH 2 .

18. The compound of claim 15 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —H, —CN, —O—C 1-3 , —CF 3 , or halogen.

19. The compound of claim 15 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —CN.

20. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula Ic:

or a tautomer or pharmaceutically acceptable salt thereof.

21. The compound of claim 20 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are —CH 3 .

22. The compound of claim 20 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 2 is —NH 2 .

23. The compound of claim 20 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —H, —CN, —O—C 1-3 alkyl, —CF 3 , or halogen.

24. The compound of claim 20 , or a tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is —CN.

25. The compound of claim 1 , wherein the compound is selected from:

or a tautomer or pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

27. A method for treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof.

28. A method for treating an HIV infection in a subject comprising administering to the subject in need thereof a compound of claim 1 , or a tautomer or pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents independently selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.

Assignees

• Gilead Sciences Inc
• Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I

Inventors

• Jansa Petr
• Kvasnica Miroslav
• Mackman Richard L

Classifications

• A61P31/18

  for HIV · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title